Shanghai Fosun Pharmaceutical Group Co Ltd (600196) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.
Total Revenue Chart for Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) revenue for FY2025 was CNY 41.5B, a 1.1% change from FY2024. Shanghai Fosun Pharmaceutical Group Co Ltd's revenue grew from CNY 64.7M in 1995 to CNY 41.5B in 2025 (64094.5% over 30 years). Earnings per share grew from CNY 0.07 in 2000 to CNY 1.43 in 2022 (1857.7%). Revenue compound annual growth rate: 5-year CAGR of 6.5%, 10-year CAGR of 12.7%, 20-year CAGR of 14.1%.
Total Revenue (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥61.77B
- Implied Share Price
- ¥29.16
- Enterprise Value
- ¥82.32B
- Revenue (TTM)
- ¥42.59B
- EBITDA
- ¥5.90B
- Profit Margin
- 7.96%
- Trailing P/E
- 18.07
- Forward P/E
- 17.76
- Price/Book (MRQ)
- 1.27
- Price/Sales (TTM)
- 1.45
- EV/EBITDA
- 8.35
- EV/Revenue
- 1.93
- Dividend Yield
- 1.69%
- Book Value
- ¥18.46
- Free Cash Flow (FY2025)
- ¥1.56B
- Free Cash Flow Yield
- 2.52%
Snapshot as of 23rd September 2026 — not point-in-time controlled, may lag the live market by a few days.